Updated WADA statement,
... This updated guidance confirms that from 1 March (and up until 30 September) 2016, cases with a low concentration of meldonium found in an athlete’s sample (less than 1 μg /mL) are compatible with a no fault finding. Other cases are to be managed according to guidance by the responsible anti-doping organizations (ADOs).
Typically, WADA does not commission excretion studies for substances that are added to the List as the Agency is generally able to rely on this information being provided by the manufacturer or regulatory authorities. In the case of meldonium, however, no information relating to urinary excretion was available and so once it was added to the List, WADA undertook excretion studies.
“We are pleased that the necessary urinary excretion studies have now progressed; and that, the guidance we are now able to provide our stakeholders to help them manage meldonium cases is clear and scientifically robust,” said WADA President, Sir Craig Reedie.
“The addition of meldonium to the Prohibited List created an unprecedented situation and therefore, during a transitional period, it warranted additional guidance for those in the anti-doping community tasked with managing cases,” said Oliver Niggli, Director General. “We place full trust in the ability of our Stakeholders to manage meldonium cases effectively, and will be on hand to assist them as necessary.”
https://www.wada-ama.org/en/media/ne...ding-meldonium
... This updated guidance confirms that from 1 March (and up until 30 September) 2016, cases with a low concentration of meldonium found in an athlete’s sample (less than 1 μg /mL) are compatible with a no fault finding. Other cases are to be managed according to guidance by the responsible anti-doping organizations (ADOs).
Typically, WADA does not commission excretion studies for substances that are added to the List as the Agency is generally able to rely on this information being provided by the manufacturer or regulatory authorities. In the case of meldonium, however, no information relating to urinary excretion was available and so once it was added to the List, WADA undertook excretion studies.
“We are pleased that the necessary urinary excretion studies have now progressed; and that, the guidance we are now able to provide our stakeholders to help them manage meldonium cases is clear and scientifically robust,” said WADA President, Sir Craig Reedie.
“The addition of meldonium to the Prohibited List created an unprecedented situation and therefore, during a transitional period, it warranted additional guidance for those in the anti-doping community tasked with managing cases,” said Oliver Niggli, Director General. “We place full trust in the ability of our Stakeholders to manage meldonium cases effectively, and will be on hand to assist them as necessary.”
https://www.wada-ama.org/en/media/ne...ding-meldonium
Comment